8-K filing — Co-Diagnostics, Inc. (CODX)
Filed: 2026-09-16 AccNo: 0001493152-26-042854 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Co-Diagnostics Announces FDA Submission Of Dual 510(k) With Concurrent CLIA Waiver Application For Co-Dx PCR Flu A/B & RSV Point-Of-Care Test
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Co-Diagnostics Enters Material Transfer Agreement With ReadyGo Diagnostics To Evaluate Sample Preparation Technologies For Co-Dx PCR Platform; Material Transfer Agreement Does Not Obligate Either Party To Enter Into Any Development, Supply, Commercialization Or Other Commercial Arrangement
In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreement with ReadyGo Diagnostics Ltd ("ReadyGo") to evaluate the potential compatibility of certain ReadyGo sample
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.